Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with cancer.

Risk Factors Determine Symptom Burden Profiles by Age Group

Data from the CEPHEUS trial support the use of D-VRd in patients with transplant-ineligible or -deferred multiple myeloma who can tolerate bortezomib.

Study Findings Support D-VRd for Transplant-Ineligible or -Deferred MM

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Real-World Data Shows Apalutamide Increases 24-Month OS in mCSPC

Mobile App Appears Feasible for Cancer Survivor Cognitive Assessment Function

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Articles

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the prioritization of quality of life.

Prioritizing QOL Important to Treating HR+, HER2- Metastatic Breast Cancer

Caroline Seymour joined MJH Life Sciences in 2018 and has expertise in video production and print/digital publication. Email: cseymour@onclive.com​

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

Oncology nurses can enhance endometrial cancer recovery by fostering strong social support networks and improving communication with the patient.

Opinion: Social Support is Key to Endometrial Cancer Recovery

Biocartis announced the launch of its real-time quantitative polymerase chain reaction assay to detect POLE and POLD1 mutations in endometrial cancer.

Biocartis Launches qPCR POLE/POLD1 Mutational Assay

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by results of a real-world study.

Real-World Data Verify Safety, Efficacy of Dostarlimab/Chemo in Endometrial Cancer

Palbociclib plus letrozole lengthened PFS vs placebo plus letrozole for patients with ER-positive advanced or recurrent endometrial cancer.

Palbociclib Plus Letrozole May Increase PFS for ER+ Endometrial Cancer

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss. 

Olanzapine May Address AEs From TKIs for Kidney and Other Cancers

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.

Peer Exchange

Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

The panel shares the most critical unmet needs for patients with endometrial cancer.

Greatest Unmet Needs for Patients with Endometrial Cancer

Kimberly A. Spickes, CNP, discusses how often patients with endometrial cancer have dose reductions or interruptions at her institution, and who is involved in the decision to dose-reduce.

Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

Nurse Practitioner Kimberly Halla explains the proactive measures she takes to ensure patients with endometrial cancer are prepared to experience and manage the adverse effects of treatment.

Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer

Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.

Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

Kimberly Halla, NP, describes the standards for monitoring patients on therapy for recurrent endometrial cancer, including how often patients are seen in-person.

Monitoring Patients on Therapy for Recurrent Endometrial Cancer

The panel explains how to educate patients on the adverse effects they may experience with chemotherapy, their options for management, and the importance of encouraging patients to contact their care team.

Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

The panel reviews the second-line treatment options for patients with recurrent endometrial cancer.

Treatment Options for Patients with Recurrent Endometrial Cancer

Nurse Practitioner Kathleen Lutz talks about the efficacy of chemotherapy in patients with endometrial cancer, and how she discusses the chance of disease recurrence with patients.

Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer

Continuing her discussion, Kathleen highlights the most common adverse events she sees in patients treated with chemotherapy for advanced endometrial cancer who are unfit for surgery.

Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

Endometrial Cancer

Latest News

Latest Conference Coverage